Patent ID: 6486148
Filing Date: 2002-11-26
Classification: A61P,C07J

Abstract:
A method of treating a microbial infection of a host by administering to the host an effective amount of an anti-microbial composition comprising a compound according to formula I: wherein:fused rings A, B, C, and D are independently saturated or fully or partially unsaturated; and R1 through R4, R6, R7, R11, R12, R15, R16, and R17 is each independently selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, (C1-C10) alkylamino-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, C1-C10 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2N-HC(Q5)-C(O)-Oâ€”, H2N-HC(Q5)-C(O)-N(H)â€”, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN-CH(Q5)-C(O)-Oâ€”, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkyl carboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and R5, R8, R9, R10, R13, and R14 is each independently: deleted when one of fused rings A, B, C, or D is unsaturated so as to complete the valency of the carbon atom at that site, or selected from the group consisting of hydrogen, hydroxyl, a substituted or unsubstituted (C1-C10) alkyl, (C1-C10) hydroxyalkyl, (C1-C10) alkyloxy-(C1-C10) alkyl, a substituted or unsubstituted (C1-C10) aminoalkyl, a substituted or unsubstituted aryl, C1-C10 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, a linking group attached to a second steroid, a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, H2N- HC(Q5)-C(O) Oâ€”, H2N- C(Q5)-C(O)-N(H)â€”, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN-CH(Q5)-C(O)â€”Oâ€”, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy, where Q5 is a side chain of any amino acid, P.G. is an amino protecting group, and provided that at least two of R1 through R14 are independently selected from the group consisting of a substituted or unsubstituted (C1-C10) aminoalkyloxy, a substituted or unsubstituted (C1-C10) aminoalkylcarboxy, a substituted or unsubstituted (C1-C10) aminoalkylaminocarbonyl, a substituted or unsubstituted (C1-C10) aminoalkylcarboxamido, H2Nâ€”HC(Q5)-C(O)-Oâ€”, H2N-HC(Q5)-C(O)-N(H)â€”, (C1-C10) azidoalkyloxy, (C1-C10) cyanoalkyloxy, P.G.-HN-CH(Q5)-C(O)-Oâ€”, (C1-C10) guanidinoalkyloxy, and (C1-C10) guanidinoalkylcarboxy; or a pharmaceutically acceptable salt thereof.